Andrew J. White, M.D.

James P. Keating, MD, Professor of Pediatrics
Patient Oriented Research UnitRheumatologyPediatric Residency


Clinical Interests

Dr. Andrew White received his undergraduate education at Brandeis University in Waltham, Massachusetts, spent 3 years at the University of Chicago working on derivatives of cubane in pursuit of a PhD in synthetic organic chemistry, but then decided to change course (see and earned his medical degree from the University of Texas Southwestern Medical School. Dr. White was an intern in Pediatrics at the St. Louis Children's Hospital, and then he completed a fellowship in Pediatric Immunology and Rheumatology at Washington University School of Medicine in St. Louis. He is a member of the American Academy of Pediatrics and is Board certified in both Pediatrics and Pediatric Rheumatology by the American Board of Pediatrics. Dr. White is the Program Director of the Residency Program in Pediatrics at St. Louis Children's Hospital, a position he has held since 2002, and is the former Director of Division of Pediatric Rheumatology, a position he held from 2004 until 2017. He is the Co-Director of the Washington University Hereditary Hemorrhagic Telangiectasia Center, as well as Director of Rheumatology Services at the Shriner's Hospital of St Louis. Dr White also serves as the Vice Chair of Education in the Department of Pediatrics. (see

Dr. White grew up in San Antonio, Texas and is an avid tropical fish hobbyist, specializing in the undescribed species of Loricariidae, as well as a fanatical wind-surfer and basketball player.


  • BA, Brandeis University1986
  • MSc, University of Chicago1989
  • MD, University of Texas Southwestern1994


  • Pediatric Residency, St Louis Children's Hospital1994 - 1997
  • Pediatric Rheumatology and Immunology Fellowship, Washington University1997 - 2000
  • Evidence Based Clinical Practice, McMaster University2003 - 2003
  • Leadership Development for Physicians in Academic Health Centers, Harvard University2015 - 2015
  • Advanced Management Certificate , Olin School of Business2016

Licensure and Board Certification

  • MO, 
  • American Board of Pediatrics; General Pediatrics 1999
  • American Board of Pediatrics; Pediatric Rheumatology 2000


  • Clinical Teacher of the Year, Washington University School of Medicine2004
  • Clinical Teacher of the Year, Washington University School of Medicine2007
  • Clinical Teacher of the Year, Washington University School of Medicine2010
  • POM Small-Group Leader of the Year Award, Washington University School of Medicine2010
  • AOA Honor Society, Washington University School of Medicine2011
  • Distinguished Clinician Award, Washington University School of Medicine2011
  • The Phillip R Dodge Scholar in Pediatrics, Washington University School of Medicine2014
  • Clinical Teacher of the Year, Washington University School of Medicine2015

Recent Publications view all (49)

  1. SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling. Nat Immunol. 2017;18(9):995-1003. PMID:28759002 
  2. Asymptomatic pulmonary arteriovenous malformations in children with hereditary hemorrhagic telangiectasia. Pediatr Pulmonol. 2017. PMID:28608633 
  3. An assessment of residents' and fellows' personal finance literacy: an unmet medical education need. Int J Med Educ. 2017;8:192-204. PMCID:PMC5457786  PMID:28557777 
  4. Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. J Pediatr. 2017;184:38-44.e1. PMCID:PMC5410644  PMID:28410093 
  5. Families as Partners in Hospital Error and Adverse Event Surveillance. JAMA Pediatr. 2017;171(4):372-381. PMID:28241211 
  6. The Prevalence of Malformations of Cortical Development in a Pediatric Hereditary Hemorrhagic Telangiectasia Population American Journal of Neuroradiology. 2016;1-4. 
  7. Sarcoidosis presenting as granulomatous myositis in a 16-year-old adolescent. Pediatr Rheumatol Online J. 2016;14(1):59. PMCID:PMC5105277  PMID:27832822 
  8. Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and Systemic Sclerosis. J Rheumatol. 2016;43(9):1768-9. PMID:27587018 
  9. 7-Year-Old With a Painful Rash. JAMA Pediatr. 2016;170(8):801-2. PMID:27479116 
  10. Emergency Information Forms for Children With Medical Complexity: A Simulation Study. Pediatrics. 2016;138(2). PMID:27436504 
  11. Azathioprine therapy for steroid-resistant Henoch-Schönlein purpura: a report of 6 cases. Pediatr Rheumatol Online J. 2016;14(1):37. PMCID:PMC4918135  PMID:27333803 
  12. Comparing presenting clinical features of 48 children with microscopic polyangiitis (MPA) against 183 having granulomatosis with polyangiitis (GPA). An ARChiVe study. Arthritis Rheumatol. 2016. PMID:27111558 
  13. The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations. Am J Med Genet A. 2015;167(6):1262-7. PMCID:PMC4449292  PMID:25847705 
  14. Neurovascular manifestations in hereditary hemorrhagic telangiectasia: imaging features and genotype-phenotype correlations. AJNR Am J Neuroradiol. 2015;36(5):863-70. PMCID:PMC4433843  PMID:25572952 
  15. Hemorrhage rates from brain arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. Stroke. 2015;46(5):1362-4. doi:10.1161/STROKEAHA.114.007367  PMCID:PMC4415515  PMID:25858236 
  16. Mesenteric vasculitis in children with systemic lupus erythematosus. Clin Rheumatol. 2015. doi:10.1007/s10067-015-2892-3  PMID:25687984 
  17. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125(4):591-9. doi:10.1182/blood-2014-09-602763  PMCID:PMC4304103  PMID:25359994 
  18. Severity score for hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2014;9:188. PMCID:PMC4302697  PMID:25928712 
  19. Changes in medical errors after implementation of a handoff program. N Engl J Med. 2014;371(19):1803-12. doi:10.1056/NEJMsa1405556  PMID:25372088 
  20. Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. Arthritis Care Res (Hoboken). 2014. doi:10.1002/acr.22487  PMID:25331530 
  21. C1q nephropathy in the setting of granulomatosis with polyangiitis treated with tacrolimus. Clin Kidney J. 2014;7(5):499-500. doi:10.1093/ckj/sfu087  PMCID:PMC4379345  PMID:25878789 
  22. Histogram flow mapping with optical coherence tomography for in vivo skin angiography of hereditary hemorrhagic telangiectasia. J Biomed Opt. 2014;19(8):086015. PMCID:PMC4407667  PMID:25140883 
  23. Elevated double negative T cells in pediatric autoimmunity. J Clin Immunol. 2014;34(5):594-9. doi:10.1007/s10875-014-0038-z  PMCID:PMC4047151  PMID:24760111 
  24. Scurvy revealed by difficulty walking: three cases in young children. J Clin Rheumatol. 2014;20(4):224-8. doi:10.1097/RHU.0000000000000101  PMID:24847751 
  25. Gout in a 15-year-old boy with juvenile idiopathic arthritis: a case study. Pediatr Rheumatol Online J. 2014;12(1):1. doi:10.1186/1546-0096-12-1  PMCID:PMC3895757  PMID:24393408 
  26. Hypogammaglobulinemia in pediatric systemic lupus erythematosus. Lupus. 2013;22(13):1382-7. doi:10.1177/0961203313507990  PMCID:PMC3840537  PMID:24106215 
  27. Tolosa-Hunt syndrome masquerading as Gradenigo syndrome in a teenager. Int J Pediatr Otorhinolaryngol. 2013;77(7):1219-21. doi:10.1016/j.ijporl.2013.04.023  PMID:23684166 
  28. Picture of the month. Carpal-tarsal osteolysis. JAMA Pediatr. 2013;167(3):297-8. doi:10.1001/jamapediatrics.2013.1554a  PMID:23460230 
  29. Febrile ulceronecrotic Mucha-Habermann disease with central nervous system vasculitis. Pediatr Dermatol. 2013;30(1):90-3. doi:10.1111/j.1525-1470.2011.01669.x  PMID:22276640 
  30. Imaging of juvenile idiopathic arthritis: a multimodality approach. Radiographics. 2013;33(5):1253-73. doi:10.1148/rg.335125178  PMID:24025923 
  31. The use of electroconvulsive therapy in a patient with juvenile systemic lupus erythematosus and catatonia. Lupus. 2012;21(14):1575-81. doi:10.1177/0961203312464803  PMID:23161578 
  32. Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions. J Rheumatol. 2012;39(10):2012-20. doi:10.3899/jrheum.120299  PMID:22859342 
  33. Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions. J Rheumatol. 2012;39(10):2012-20. doi:10.3899/jrheum.120299  PMID:22859342 
  34. Vancomycin-induced DRESS with evidence of T-cell activation in a 22-month-old patient. Ann Allergy Asthma Immunol. 2012;109(4):280-1. doi:10.1016/j.anai.2012.07.016  PMID:23010236 
  35. Recurrent cardiac tamponade in a child with newly diagnosed systemic-onset juvenile idiopathic arthritis. J Clin Rheumatol. 2012;18(6):304-6. doi:10.1097/RHU.0b013e3182685857  PMID:22955481 
  36. Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis. J Rheumatol. 2012;39(8):1687-97. doi:10.3899/jrheum.111352  PMID:22589257 
  37. I-pass, a mnemonic to standardize verbal handoffs. Pediatrics. 2012;129(2):201-4. doi:10.1542/peds.2011-2966  PMID:22232313 
  38. Recurrent parotitis as a presentation of primary pediatric Sjögren syndrome. Pediatrics. 2012;129(1):e179-82. doi:10.1542/peds.2011-0716  PMID:22184654 
  39. Acute genital ulcers in nonsexually active young girls: case series, review of the literature, and evaluation and management recommendations. Pediatr Dermatol. 2012;29(2):147-53. doi:10.1111/j.1525-1470.2011.01589.x  PMID:22300420 
  40. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum. 2011;63(10):3163-8. doi:10.1002/art.30502  PMID:21702011 
  41. Establishing a multisite education and research project requires leadership, expertise, collaboration, and an important aim. Pediatrics. 2010;126(4):619-22. doi:10.1542/peds.2010-1793  PMID:20876168 
  42. Ophthalmology education in pediatric residency training programs. J AAPOS. 2010;14(1):58-60. doi:10.1016/j.jaapos.2009.11.010  PMID:20227625 
  43. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107-11. doi:10.1002/art.22856  PMID:17763414 
  44. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148(2):247-53. doi:10.1016/j.jpeds.2005.10.032  PMID:16492437 
  45. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev. 2006;5(1):18-24. doi:10.1016/j.autrev.2005.05.006  PMID:16338207 
  46. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol. 2005;95(3):293-300. doi:10.1016/S1081-1206(10)61228-8  PMID:16200822 
  47. Swollen uvula in an 18-year-old man with hypogammaglobulinemia. Ann Allergy Asthma Immunol. 2004;93(5):417-24. doi:10.1016/S1081-1206(10)61407-X  PMID:15562879 
  48. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31(10):2071-5. PMID:15468378 
  49. The mechanism of olefin-to-carbene rearrangement for 9-phenyl-1(9)-homocubene. 1990; 55(4):1321. J Org Chem . 1990;55(4):1321. 
Last updated: 10/18/2017
© 2018 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130